Jobs
Properties
Automarket
Databank
EasyBanking
Search
Categories
Companies
People
Sectors
Topics
Business
Events
Conferences
Local trade exhibitions
International trade exhibitions
Professional
Training
Executive training
Trade
Missions
Incoming
Outgoing
Weekly
Newsletter
View latest issue
Subscribe
Update my subscription
Unsubscribe
SUBMIT INFO
News
Conferences
Exhibitions
Tenders
Training
Missions
Search
Categories
Financial
Markets
Business
Events
Trade
Missions
Business
Research
Calculation
Tools
Weekly
Newsletter
SUBMIT INFO
CHAMPION OF THE DAY
LEADERS NEWS
3,000 medicines
to be re-priced
Average reduction is
estimated to be 40 percent
The Ministry of Public Health (MoPH) will step up its efforts to re-price medication to reduce healthcare costs across the board.
Every five years the ministry compares the cost of thousands of medicines against those costs in seven reference countries, and adopts the lowest price. The MoPH will speed up that cycle in January, and re-price medication every three years and pass those savings to consumers. Medication, generally, drops in price the longer it is on the market, especially after pharmaceutical companies recoup their costs, and generics become available.
The ministry will re-evaluate the prices of 1,600 drugs starting in January. It expects to re-price some 3,400 of the 5,000 registered medications in 2019, said the MoPH.
Customers can expect to save an average of 40 percent on medication, with some reductions reaching 70 percent.
An additional 300 generic imported medicines will be re-priced because their prices should be ten percent lower than that of the originator. The price of local generics will not be reduced, in order “to support the local pharmaceutical industry,” said the MoPH.
The ministry last year allowed pharmacists to replace imported generics with locally-manufactured versions. It also removed Customs levies on raw materials needed to manufacture pharmaceuticals.
The average annual pharmaceutical expenditure per capita is $244, and is expected to drop to $144, with an equivalent amount by the government represented by insurance funds such as National Social Security Fund, and Internal Security Fund, and others. This adds the national pharma cost to $288, post decrease. In Europe it is $550, and in the United State $1,600.
Reported by Rania Ghanem
Your browser does not support iframes.
Date Posted:
Dec 21, 2018
Your browser does not support inline frames
ABOUT
ADVERTISE
SUBMIT INFO
RSS
CONTACT US
©
2021 by InfoPro sal. All Rights Reserved